Cardiac Biomarkers: Technologies and Global Markets

Jun 2016| BIO128B| BCC Publishing

Report Highlights

The global cardiac biomarkers market has grown to $4.9 billion in 2015 from $4.4 billion in 2014. The market is expected to grow at a five-year compound annual growth rate (CAGR) of 12.4% from 2015 to 2020, increasing to over $8.8 billion in 2020.

Report Includes

  • An overview of the global market for cardiac biomarkers and related technologies.
  • Analyses of global market trends, with data from 2014, 2015, and projections of CAGRs through 2020.
  • Classification of cardiac biomarkers by cerebrovascular, congestive, coronary, hypertensive, and peripheral arterial disease.
  • Background and clinical values of cardiac biomarkers, including B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP), choline, creatine kinase MB (CK-MB), D-dimer, glial fibrillary acidic protein (GFAP), heart fatty acid binding protein (H-FABP), ischemia-modified albumin (IMA), myeloperoxidase (MPO), myoglobin, soluble fragment CD40 ligand (sCD40L), and troponin I (cTnI)/troponin T (cTnT).
  • Examination of the technology covering diagnostic methods, instrumentation, newly issued patents, and new patent applications.
  • Clinical guidelines and government regulations.
  • Profiles of major players in the industry.

Report Scope

Current and projected assay revenues during the forecast period (2015 through 2020) are presented. In addition, newly developed assays with regulatory approval and others expected to receive U.S. Food and Drug Administration approval within the forecast period are also projected. Figures for 2015 are estimated, except where actual results have been reported, because of the timing of the release of this report. For large market segments, such as cTn and natriuretic peptides, the analytical sensitivities and cutoff references for the diagnosis and prognosis values are discussed in detail. Moreover, the ongoing effort in developing a high-sensitivity troponin assay, as well as the attempt to pursue additional biomarkers for the diagnosis of congestive heart failure (CHF) and strokes are focused on in this study.

The report includes an analysis of leading and emerging competitors in the current global diagnostics market for CVDs. Profiles of manufacturers of leading products as well as biotechnology companies with products in development are discussed to define their specific product strategies. The competitive environment is examined, with a special focus on how instrumentation type (clinical chemistry analyzers compared with point-of-care devices) and their respective technologies are influencing the current standard of care. Detailed profiles of current market leaders are discussed, as well as companies with innovative products poised to enter the market during the forecast period.

Market figures are based on revenues at the manufacturers’ level and are projected at 2015-U.S.-dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, new product introductions, expanded indications for existing products and projected changes in the prevalence and diagnosis of respective diseases. Included in this report are forecasts by product, product category and by company from 2014 through 2020. The study is arranged to offer an overview of the diagnostics market accompanied by product, company and region.

Excluded from this report are nonproteomic diagnoses (i.e., molecular diagnostics), imaging technology and pharmaceutical biomarkers. Sales figures are reported in U.S. dollars, and in each case, these reflect currency fluctuations within the performance of changes in sales. Sales figures do not account for variation in local currencies. All market share data presented are on a global basis, unless specifically noted.

Frequently Asked Questions (FAQs)

Analyst Credentials

ANUJ PATHAK has written and researched the global medical device market, surgical instruments and biotechnology market. Skilled in information technology and computer management, he has an undergraduate business degree and an MBA degree.

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Cardiac Biomarkers: Technologies and Global Markets191Free
Published - Mar-2014| Analyst - Cheng-Yuk Lee| Code - BIO128A

Report Highlights

The global market for in vitro diagnostic tests for cardiac biomarkers was estimated at $3.1 billion in 2012 and nearly $4 billion in 2013. This market is predicted to reach $7.2 billion by 2018, at a compound annual growth rate (CAGR) of 12.8% over the five-year period from 2013 to 2018.

Report Includes

  • An overview of the global market for biomarkers for cardiovascular disease (CVD) and related technologies.
  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of CAGRs for the period 2013 to 2018.
  • Classification of CVD by cerebrovascular, congestive, coronary, hypertensive, and peripheral arterial disease.
  • Background and clinical values of cardiac biomarkers, including B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP), choline, creatine kinase MB (CK-MB), D-dimer, glial fibrillary acidic protein (GFAP), heart fatty acid binding protein (H-FABP), ischemia-modified albumin (IMA), myeloperoxidase (MPO), myoglobin, soluble fragment CD40 ligand (sCD40L), and troponin I (cTnI)/troponin T (cTnT).
  • Examination of the technology covering diagnostic methods, instrumentation, newly issued patents, and new patent applications.
  • Clinical guidelines and government regulations.
Cardiac Biomarkers: Technologies and Global Markets

Single User License: $2500

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
RELATED REPORTS